MedWatch

Galecto CEO celebrates super investment: "It's fantastic"

Hans Schambye, CEO in Danish Galecto Biotech, is very content with last week's million-dollar investment in his company from new as well as current investors.

The Galecto Biotech team with CEO Hans Schambye in the middle. | Foto: Henriette Bonde

CEO in Danish biotech company Galecto, Hans Schambye, is without doubt a happy man these days.

On October 26, his company raised DKK 590 million (USD 89.9 million) in a series C financing round with participation from, for instance, US drug group Bristol-Myers Squibb and the Novo-owned venture fund Novo Seeds.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier